Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Regeneron Announces Upcoming Investor Conference Presentations

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations as follows:

REGN : 300.19 (-0.46%)
Global Ophthalmic Drugs Market, Current Trends, Competitive Landscape and Forecasts till 2022

The Global Ophthalmic Drugs Market was valued at US$ XX Mn in 2016 and is expected to reach US$ XX Mn by 2022 growing at a CAGR of XX% during the forecast period . As seen, the ophthalmic industry is a...

BAYRY : 18.1900 (-0.49%)
PFE : 36.46 (unch)
REGN : 300.19 (-0.46%)
VRX.TO : 30.80 (-3.33%)
Alexion Pharm has the Best Relative Performance in the Biotechnology Industry (ALXN , INCY , REGN , AMGN , BIIB )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

ALXN : 98.41 (-1.58%)
INCY : 77.76 (+0.43%)
REGN : 300.19 (-0.46%)
Regeneron Pharm Set to Possibly Pullback After Yesterday's Rally of 2.55%

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $298.90 to a high of $305.98. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high...

REGN : 300.19 (-0.46%)
Wet AMD Space in Focus: New Drug Approvals & Key Advancements

The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.

RHHBY : 36.8100 (+0.68%)
BAYRY : 18.1900 (-0.49%)
AGN : 173.60 (+0.64%)
NVS : 86.88 (-0.40%)
REGN : 300.19 (-0.46%)
RGNX : 37.75 (-3.28%)
Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study

Dermira (DERM) starts a phase III program for evaluation of its monoclonal antibody candidate, lebrikizumab, in adolescents and adult patients with atopic dermatitis, the most common form of eczema.

LLY : 108.64 (+0.17%)
SNY : 46.17 (-0.71%)
REGN : 300.19 (-0.46%)
DERM : 7.16 (+25.83%)
Regeneron to Report Third Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2019

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2019 financial and operating results on Tuesday, November 5, 2019, before the U.S. financial markets...

REGN : 300.19 (-0.46%)
Novartis' (NVS) Wet AMD Drug Beovu Obtains FDA Approval

Novartis (NVS) wins FDA approval for Beovu injection for the treatment of wet AMD at a three-month dosing interval.

NVS : 86.88 (-0.40%)
RHHBY : 36.8100 (+0.68%)
BAYRY : 18.1900 (-0.49%)
REGN : 300.19 (-0.46%)
Look for Shares of Regeneron Pharm to Potentially Pullback after Yesterday's 1.15% Rise

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $280.66 to a high of $287.77. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high...

REGN : 300.19 (-0.46%)
Regeneron Pharm Down 5.2% Since SmarTrend Downtrend Call (REGN)

SmarTrend identified a Downtrend for Regeneron Pharm (NASDAQ:REGN) on July 11th, 2019 at $292.50. In approximately 3 months, Regeneron Pharm has returned 5.16% as of today's recent price of $277.40.

REGN : 300.19 (-0.46%)
Pfizer's JAK1 Inhibitor Meets All Goals in 2nd Phase III Study

Pfizer's (PFE) investigational eczema candidate abrocitinib meets all co-primary and secondary endpoints as a monotherapy in the second pivotal late stage study.

SNY : 46.17 (-0.71%)
PFE : 36.46 (unch)
LLY : 108.64 (+0.17%)
REGN : 300.19 (-0.46%)
Regeneron Pharm Set to Possibly Rebound After Yesterday's Selloff of 2.09%

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $280.27 to a high of $287.70. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of...

REGN : 300.19 (-0.46%)
Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late

Sanofi's (SNY) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

MRK : 84.68 (+1.05%)
NVS : 86.88 (-0.40%)
SNY : 46.17 (-0.71%)
REGN : 300.19 (-0.46%)
Global Ophthalmic Drugs Market, Current Trends, Competitive Landscape and Forecasts, till 2022

The Global Ophthalmic Drugs Market was valued at US$ XX Mn in 2016 and is expected to reach US$ XX Mn by 2022 growing at a CAGR of XX% during the forecast period . As seen, the ophthalmic industry is a...

BAYRY : 18.1900 (-0.49%)
PFE : 36.46 (unch)
REGN : 300.19 (-0.46%)
VRX.TO : 30.80 (-3.33%)
Biotech Stock Roundup: Pipeline Updates From REGN, BIIB, AMGN and More

Key highlights of the past week include regulatory and pipeline updates, licensing deals, and more.

CLVS : 3.34 (-8.74%)
BIIB : 220.06 (-2.46%)
AMGN : 202.72 (-0.41%)
REGN : 300.19 (-0.46%)
ZEAL : 26.75 (-1.64%)
Proliferative Diabetic Retinopathy Market – Global Sales, Ex-Factory Price, Revenue, Gross Margin Analysis 2026

In 2018, the Proliferative Diabetic Retinopathy Market revenue was around US$ XX Mn and the Market share was XX%, and it will be projected to reach US$ XX Mn and XX% in 2026, with a CAGR XX% during the...

AGN : 173.60 (+0.64%)
MRK : 84.68 (+1.05%)
MKKGY : 23.6900 (+0.21%)
NVS : 86.88 (-0.40%)
REGN : 300.19 (-0.46%)
VRX.TO : 30.80 (-3.33%)
Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent

Regeneron (REGN) and Sanofi get positive CHMP recommendation for the label expansion of asthma drug Dupixent in an additional indication.

SNY : 46.17 (-0.71%)
AMGN : 202.72 (-0.41%)
ALNY : 84.78 (+3.54%)
REGN : 300.19 (-0.46%)
The Zacks Analyst Blog Highlights: Target, Illumina, T-Mobile US, Xcel and Regeneron

The Zacks Analyst Blog Highlights: Target, Illumina, T-Mobile US, Xcel and Regeneron

XEL : 64.01 (+0.53%)
ILMN : 309.44 (-0.36%)
REGN : 300.19 (-0.46%)
TGT : 112.81 (-0.37%)
TMUS : 81.60 (+0.68%)
McDermott and Scholastic rise while Xilinx and KeyCorp fall

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Friday.

REGN : 300.19 (-0.46%)
RBS : 6.13 (+3.37%)
RBS.LS : 238.300 (+2.63%)
XLNX : 94.34 (-0.60%)
SCS : 18.14 (-0.17%)
SCHL : 37.99 (+0.58%)
Top Research Reports for Target, Illumina & T-Mobile US

Top Research Reports for Target, Illumina & T-Mobile US

XEL : 64.01 (+0.53%)
TMUS : 81.60 (+0.68%)
TGT : 112.81 (-0.37%)
REGN : 300.19 (-0.46%)
ILMN : 309.44 (-0.36%)
DD : 65.53 (-1.06%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +4.48 , AIZ -0.27 , SBAC +4.06 , SO +0.08 , WELL +0.91
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar